Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo

Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo

Source: 
Fierce Pharma
snippet: 

The Opdivo-Yervoy regimen is now FDA-approved to treat hepatocellular carcinoma patients who have previously received Bayer’s standard-of-care Nexavar, Bristol said Wednesday. Because the FDA doled out the indication under an accelerated approval based on tumor response numbers, the company is required to run confirmatory trials.